Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas

BMC Clinical Pathology

Table 6 Co-expression of ER/PGR and their prediction for disease-specific survival in patients with soft tissue sarcomas (univariate analysis; log-rank test)

Co-expression	Patients (n)	Patients (%)	Median survival (months)	5-year survival (%)	P
ER / PGR, all, N = 193
Low/low	84	44	NR	69	<0.001
Low/high	26	13	38	24
High/low	41	21	62	52
High/high	31	16	NR	64
Missing	11	6
ER / PGR, men, N = 81
Low/low	39	48	NR	79	0.013
Low/high	9	11	41	33
High/low	23	28	63	53
High/high	6	7	37	33
Missing	4	5
ER / PGR, women, N = 121
Low/low	45	40	89	59	0.001
Low/high	17	15	31	19
High/low	18	16	29	50
High/high	25	22	NR	72
Missing	7	6
ER / PGR, <60 years, N = 99
Low/low	41	41	NR	72	0.001
Low/high	13	13	31	23
High/low	19	19	NR	58
High/high	21	21	NR	76
Missing	5	5
ER / PGR, ≥60 years, N = 94
Low/low	43	46	NR	64	0.052
Low/high	13	14	39	26
High/low	22	23	58	47
High/high	10	11	37	40
Missing	6	6
ER / PGR, Skp2 low, N = 109
Low/low	55	50	NR	76	0.068
Low/high	9	8	68	25
High/low	23	21	91	61
High/high	16	15	75	56
Missing	6	6
ER / PGR, Skp2 high, N = 67
Low/low	21	31	89	55	0.005
Low/high	14	21	31	29
High/low	17	25	29	42
High/high	13	19	NR	77
Missing	2	3

ISSN: 1472-6890